Another study of MPTP found that LSN862 (LSN), a novel non-thiazolidinedione partial PPAR- γ agonist, exerted neuroprotective effects in a mouse model of PD by increasing PPAR- γ and PGC1-α expression (Swanson et al., 2013). This evidence concerns the gene PPARGC1A and Parkinson disease.